Inventor · disambiguated record
Hergen Spits
Also filed as: SPITS HERGEN
29 granted patents·10 pending applications·190 citations·filing 1994–2024
96Inventor score
Files withKLING BIOTHERAPEUTICS B V9AIMM THERAPEUTICS BV7SPITS HERGEN7ACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM4MEDIMMUNE LTD4
Top patents by PatentIndex Score
39 records- 0195US8562996B2RSV-specific binding molecules and means for producing themSPITS HERGEN·Filed 2008·Granted Oct 22, 2013·33 cites·18 claims
- 0291US10059757B2RSV-specific binding molecules and means for producing themMEDIMMUNE LTD·Filed 2016·Granted Aug 28, 2018·8 cites·32 claims
- 0390US10730931B2RSV-specific binding molecules and means for producing themMEDIMMUNE LTD·Filed 2018·Granted Aug 4, 2020·3 cites·34 claims
- 0488US9321831B2RSV-specific binding molecules and means for producing themMEDIMMUNE LTD·Filed 2013·Granted Apr 26, 2016·8 cites·23 claims
- 0587US9206247B2Means and methods for producing high affinity antibodiesBEAUMONT TIM·Filed 2011·Granted Dec 8, 2015·7 cites·18 claims
- 0687US9127251B2Means and methods for influencing the stability of antibody producing cellsSPITS HERGEN·Filed 2006·Granted Sep 8, 2015·10 cites·20 claims
- 0787US8389281B2Materials and methods relating to the production and maintenance of cell linesSPITS HERGEN·Filed 2009·Granted Mar 5, 2013·11 cites·2 claims
- 0886US9005974B2Means and methods for influencing the stability of cellsSPITS HERGEN·Filed 2005·Granted Apr 14, 2015·5 cites·9 claims
- 0981US8318487B2Materials and methods relating to the production and maintenance of cell linesSPITS HERGEN·Filed 2002·Granted Nov 27, 2012·11 cites·9 claims
- 1081US5837232AUse of an interleukin-10 antagonist to treat a B cell mediated autoimmune disorderSCHERING CORP·Filed 1995·Granted Nov 17, 1998·30 cites·7 claims
- 1180US7964406B2Means and methods for producing a stabilized cell of interestAMC AMSTERDAM·Filed 2005·Granted Jun 21, 2011·13 cites·6 claims
- 1278US9273118B2Means and methods for producing high affinity antibodiesBEAUMONT TIM·Filed 2010·Granted Mar 1, 2016·2 cites·7 claims
- 1378US2024425566A1Ex vivo antibody productionKLING BIOTHERAPEUTICS B V·Filed 2024·Application pending·0 cites
- 1474US9718874B2Influenza A virus specific antibodiesSPITS HERGEN·Filed 2012·Granted Aug 1, 2017·2 cites·9 claims
- 1573US2023242667A1Means and methods for counteracting myeloproliferative or lymphoproliferative disordersKLING BIOTHERAPEUTICS B V·Filed 2023·Application pending·0 cites
- 1672US2024360239A1Therapeutic Anti-CD9 AntibodyKLING BIOTHERAPEUTICS B V·Filed 2024·Application pending·0 cites
- 1771US2020325213A1Rsv-specific binding molecules and means for producing themMEDIMMUNE LTD·Filed 2020·Application pending·0 cites
- 1869US10774308B2Means and methods for influencing the stability of cellsACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM·Filed 2018·Granted Sep 15, 2020·0 cites·20 claims
- 1969US5776451AUse of interleukin-10 in adoptive immunotherapy of cancerSCHERING CORP·Filed 1994·Granted Jul 7, 1998·29 cites·20 claims
- 2067US12084681B2Ex vivo antibody productionKLING BIOTHERAPEUTICS B V·Filed 2019·Granted Sep 10, 2024·0 cites·19 claims
- 2165US11999793B2Therapeutic anti-CD9 antibodyKLING BIOTHERAPEUTICS B V·Filed 2021·Granted Jun 4, 2024·0 cites·16 claims
- 2265US2023235018A1Aml antigens and uses thereofKLING BIOTHERAPEUTICS B V·Filed 2022·Application pending·0 cites
- 2364US11629200B2Means and methods for counteracting myeloproliferative or lymphoproliferative disordersKLING BIOTHERAPEUTICS B V·Filed 2020·Granted Apr 18, 2023·0 cites·16 claims
- 2464US2017009205A1Ex vivo antibody productionAIMM THERAPEUTICS BV·Filed 2014·Application pending·0 cites
- 2562US10273454B2Means and methods for influencing the stability of antibody producing cellsACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM·Filed 2017·Granted Apr 30, 2019·0 cites·6 claims
- 2660US10077427B2Means and methods for influencing the stability of cellsACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM·Filed 2015·Granted Sep 18, 2018·0 cites·7 claims
- 2760US5833976AUse of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicitySCHERING CORP·Filed 1995·Granted Nov 10, 1998·9 cites·25 claims
- 2858US9822339B2Means and methods for influencing the stability of antibody producing cellsACADEMISCH MEDISCH CENTRUM BIJ DE UNIV VAN AMSTERDAM·Filed 2015·Granted Nov 21, 2017·0 cites·10 claims
- 2957US10556963B2Means and methods for counteracting myeloproliferative or lymphoproliferative disordersAIMM THERAPEUTICS BV·Filed 2014·Granted Feb 11, 2020·0 cites·16 claims
- 3057US5837293AUse of interleukin-10 analogs for antagonists to treat endotoxin- or superantigen-induced toxicitySCHERING CORP·Filed 1995·Granted Nov 17, 1998·9 cites·18 claims
- 3155US10344076B2Means and methods for producing high affinity antibodiesAIMM THERAPEUTICS BV·Filed 2016·Granted Jul 9, 2019·0 cites·9 claims
- 3254US11136407B2Therapeutic anti-CD9 antibodyAIMM THERAPEUTICS BV·Filed 2017·Granted Oct 5, 2021·0 cites·31 claims
- 3354US2009217403A1Means and methods for generating a t cell against an antigen of interestSPITS HERGEN·Filed 2006·Application pending·0 cites
- 3452US11524989B2AML antigens and uses thereofKLING BIOTHERAPEUTICS B V·Filed 2016·Granted Dec 13, 2022·0 cites·9 claims
- 3550US9969795B2Means and methods for producing high affinity antibodiesAIMM THERAPEUTICS BV·Filed 2015·Granted May 15, 2018·0 cites·8 claims
- 3650US2024317880A1Epithelial Cadherin-Specific AntibodiesKLING BIOTHERAPEUTICS B V·Filed 2021·Application pending·0 cites
- 3748US2014037618A1Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutantsGENENTECH INC·Filed 2013·Application pending·0 cites
- 3843US2017313766A1Influenza a virus specific antibodiesAIMM THERAPEUTICS BV·Filed 2017·Application pending·0 cites
- 3934US10690658B2Means and methods for determining T cell recognitionAIMM THERAPEUTICS BV·Filed 2015·Granted Jun 23, 2020·0 cites·30 claims
Join the waitlist — get patent alerts
Get an alert when Hergen Spits files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →